Table 2.

Main trials of ICIs in adjuvant and neoadjuvant setting

Name	Drugs	Setting	Phase	Results
CheckMate-9DX NCT03383458	Nivolumab vs. placebo	Adjuvant after curative resection or ablation	III	Pending Completion date: June 2025
KEYNOTE-937 NCT03867084	Pembrolizumab vs. placebo	Adjuvant after curative resection or ablation	III	Pending Completion date: June 2025
JUPITER 04 NCT03859128	Toripalimab	Adjuvant after curative resection	II/III	Pending Completion date: April 2024
NCT04639180	Camrelizumab plus apatinib	Adjuvant after curative resection or ablation	III	Pending Completion date: July 2024
EMERALD-2 NCT03847428	Durvalumab plus bevacizumab or durvalumab vs. placebo	Adjuvant after curative resection or ablation	III	Pending Completion date: September 2023
IMbrave-050 NCT04102098	Atezolizumab plus bevacizumab	Adjuvant after curative resection or ablation		Pending Completion date: August 2027
NCT04615143	Tislelizumab	Neoadjuvant for resectable recurrent HCC	II	Pending Completion date: June 2022
NCT03916627	Cemiplimab	Neoadjuvant for Resectable HCC	II	Pending Completion date: August 2027
NCT03867370	Toripalimab	Neoadjuvant for resectable HCC or ICC	I/II	Pending Completion date: November 2021
NIVOLEP NCT03630640	Nivolumab	Neoadjuvant in patients eligible for electroporation (single nodule>3 cm < 5 cm, multinodular) adjuvant after electroporation	II	Pending Completion date: September 2020
NCT04123379	Nivolumab plus anti-IL-8 or oral CCR2/5-inhibitor	Neoadjuvant for resectable HCC and adjuvant after surgery	II	Pending Completion date: October 2024
NCT03510871	Ipilimumab plus nivolumab	Neoadjuvant for HCC potentially eligible for curative surgery	II	Pending Completion date: December 2022
PRIME-HCC NCT03682276	Ipilimumab plus nivolumab	Neoadjuvant for resectable HCC	Ib	Pending Completion date: September 2022
NCT04297202	SHR-1210 (anti PD-1) plus apatinib	Neoadjuvant for resectable HCC and adjuvant treatment after surgery	II	Pending Completion date: December 2021